Basic↦Quality and Risk↦Risk-Based Approach to Quality↦Definition
What is it? Why is it important?
A Risk-Based-Approach is a decision-making process that includes ways to identify, assess, manage, and control risks associated with an activity.
In studies, this relates to risks that threaten the integrity of study identified “Critical-to-Quality” (CtoQ) factors, such as the:
- Protection of study participants (e.g. safety, rights)
- Implementation of a fit for purpose study design
- Quality of study data and its ability to answer the research question (e.g. study endpoint / outcome)
A Risk-Based-Approach means to:
- Systematically identify CtoQ factors early during study planning, protocol development, and process mapping
- Identify risks potentially able to threaten the CtoQ factors of the study
- Assess the likelihood of risk occurrence, detectability, and expected impact on CtoQ factors
- Prioritise risks, and define risk control-measures proportionate to risk significance.
A Risk-Based-Approach requires a “Quality-by-Design” (QbyD) approach. The aim is to manage risks before they occur, thereby providing credible and useful study results.
More
A risk-based approach means to:
- Communicate, train and continuously engage staff and stakeholders on risk control-measures, with a clear understanding of roles and responsibilities
- Continuously review and adapt risk control-measures for ongoing applicability and effectiveness
- Document risk control-measures, their potential deviations and improvement in real time
Applying a risk-based approach provides the opportunity to focus on the most risk relevant tasks needed for study conduct.
What do I need to do?
As a SP-INV, familiarise yourself with how to identify Critical-to-Quality (CtoQ) factors, and how to identify and assess risks that threaten their integrity.
Assess how risks impact the:
- Safety and rights of study participants (e.g. study risk-benefit ratio)
- The quality of study data and the handling of biological material (e.g. sample workflow)
- Feasibility of the planned study design
- Recruitment of the study population
- Ability to reach study outcome/endpoint (e.g. participant compliance, responsibility and oversight)
- Overall required quality aspects of the study (e.g. staff training, resources)
As a Site-INV, support the SP-INV in the identification of risks to CtoQ factors that are applicable to the setting of the participating study site.
As a SP-INV, upon risk identification:
- Focus on risks that occur as a result of study conduct (i.e. implementation of study processes and procedures)
- Implement appropriate risk control-measures in accordance with level of risk
- Invest resources in those areas where risks may have the greatest negative impact
More
Proactively identify the CtoQ factors of your study, including potential risks, early on during study planning. Use a Quality-by-Design (QbyD) approach throughout the trial lifecycle.
The Swiss law defines risks based on study risk category and type of intervention.
- Example of risk categorisation in ClinO studies:
- Medicinal product studies have risk categories A, B and C, with category C having the highest risk
- Other clinical trial studies have risk categories A and B, with risk category B having the highest risk
- Risks depend on target population, with consenting adults having the lowest risk compared to vulnerable populations:
- Children and adolescents
- Participant without capacity
- Participants in an emergency situation
- Risks are assessed based on type of intervention, such as studies:
- With or without expected direct benefit
- With or without minimal risks and burdens
Depending on risk, the required risk management and its potential strategy within a given study can vary greatly.
Depending on risk, the required risk management and its potential strategy within a given study can vary greatly.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular
- 3.10 Quality Management
ICH E8(R1) for Quality by Design and Critical-to-Quality factors
ISO 31000 (access liable to costs) – see in particular section
- Risk management: Principles and guidelines
Swiss Law
HRA – see in particular article and chapter
- Art. 12 Risks and burdens
- Chapter 3 Additional requirements for research involving vulnerable persons
ClinO – see in particular article
- Art. 19 Categorisation of studies with medicinal products